Bei Jing Shang Bao·2025-10-14 10:47Core Points - Fosun Pharma's subsidiary, Fosun Wanguo, has received notification from the National Medical Products Administration (NMPA) regarding the withdrawal of the registration application for the drug Dihydrosuccinimide Capsules [1] - The drug is an innovative small molecule chemical drug intended primarily for the treatment of non-small cell lung cancer (ALK+ and ROS1+) [1] - The registration application for the drug was accepted in March for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are ALK positive [1] - The withdrawal of the registration application does not signify the termination of the project; Fosun Wanguo plans to improve the registration materials according to the latest technical requirements from the NMPA and will resubmit the application [1]